ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.

ProKidney Corp. Class A Ordinary Shares

ProKidney is a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), aiming to preserve kidney function in patients who face limited options for care, according to self-described claims.

COM:PROKIDNEY

ProKidney

Last Close

1.74

22/11 21:00

Market Cap

216.27M

Beta: -

Volume Today

370.91K

Avg: -